Key result
A new generation of oral anticoagulant drugs is emerging as viable alternatives to vitamin K antagonists for patients with atrial fibrillation.
Why the study?
Do new generation oral anticoagulant drugs prevent ischemic stroke or thromboembolism in patients with atrial fibrillation compared to vitamin K antagonists?
Do new generation oral anticoagulant drugs prevent ischemic stroke or thromboembolism in patients with atrial fibrillation compared to vitamin K antagonists?
New oral anticoagulants are emerging as viable alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Newer anticoagulants may serve as VKA alternatives in AF; leaves open need for confirmatory randomized trials.
Atrial fibrillation (AF) confers an increased risk of ischemic stroke or thromboembolism that is reduced by long-term oral anticoagulant therapy. Until recently, the latter has typically been one from the vitamin K antagonist (VKA) class of drugs. Although highly effective, VKAs have limitations, and their use is challenging for both patients and clinicians. A new generation of oral anticoagulant drugs is emerging, including several drugs that appear to be viable alternatives to VKAs in AF patients.
No takes yet. Share an insight, caveat, or question.
Potpara et al. (2011) conducted a review in Atrial fibrillation. New generation of oral anticoagulant drugs vs. Vitamin K antagonists (VKAs) was evaluated. A new generation of oral anticoagulant drugs is emerging as viable alternatives to vitamin K antagonists for patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: